BIOGRAPHICAL SKETCH

Provide the following information for the Senior/key personnel and other significant contributors.
Follow this format for each person. **DO NOT EXCEED FIVE PAGES**.

NAME: Sanjoy Chatterjee

POSITION TITLE: Senior Consultant, Department of Radiation Oncology

EDUCATION/TRAINING *(Begin with baccalaureate or other initial professional education, such as nursing, include postdoctoral training and residency training if applicable. Add/delete rows as necessary.)*

INSTITUTION AND LOCATION	DEGREE *(if applicable)*	Completion Date MM/YYYY	FIELD OF STUDY
University of Calcutta	MBBS	09/1998	Medicine
Royal College of Physicians of UK	MRCP UK	09/2001	General Medicine
Royal College of Radiologists of UK	FRCR (Clinical Oncology)	2006	Clinical Oncology
Post Graduate Certificate in Medical Education	University of Dundee	2009	Medical education

A. Personal Statement

Having trained as an undergraduate in medicine in India I traveled to the UK and completed a structured training program in General Medicine and then specialized in Clinical Oncology. With the extensive challenges in oncology I started my career as a consultant clinical oncologist in the UK and set up a new cancer centre in Newcastle upon Tyne along with my colleagues. I led the commissioning of Helical Tomotherapy and set up to date head and neck and breast cancer protocols as I started sub specializing in treatment of these two sites of cancers. In doing so I updated the UK National consensus management guidelines on head and neck cancer and became a council member of the British Associaton of Head and Neck surgery. Having received the prestigious “Short Project Grant” from the Royal College of Radiologists in UK, I completed a prospective study on the role of metabolic imaging (FDG PET-CT) in radiotherapy planning of oropharyngeal cancers. I had the tremendous opportunity to set up a state of the art cancer centre in Kolkata, my native town and relocated back to India to set up quality assured processes in radiotherapy service research and education. I have also led the implementation of the Fellowship of the RCR examinations in India and been the pivotal person to set up India’s first clinical oncology and research certificate program.

As PI on various investigator initiated clinical studies, I have completed very interesting work related to the head and neck cancer radiotherapy especially for treatment planning (Vortigern study: ISRCTN 33175361, UKCRN ID: 08/h0907/127) and to explore reduction in radiotherapy morbidity (CARSREL study:CTRI: 2012/12/004286), or improve cure rates (INTELHOPE study: NCT02757222). I have received funding from Indian grant agencies to conduct the study. In addition, I have commissioned and propagated the use of evidence-based breast cancer radiotherapy and systemic therapy in India, I am the PI of India’s first multicenter collaborative adjuvant breast radiotherapy study addressing a novel hypofractionated RT schedule (NCT03788213) where several of the centers in this study are participating. I have also been site specific PI in multicentric sponsored clinical trials of head and neck cancers and breast cancers. I am also the PI of India’s first annotated radiotherapy image banking study (CHAVI: NCT04249895). These funded investigator initiates studies are the first of its kind and required significant collaborative grant application and close supervision and

implementation. Within these studies I have successfully managed and completed as well as initiated new clinical trials. This includes appropriate grant management and communication with co investigators.

B. Positions and Honors

Positions and Employment

2000-2001	Senior House Officer, Wrexham Maelor Hospital, North Wales
2001-2002	Senior House Officer, Lincoln County Hospital, England
2002-2006	Specialist Registrar- Scottish Training-Ninewells Hospital, Dundee and Research posts Royal Marsden Hospital London and Christie Hospital Manchester
2006- 2010	Consultant Clinical Oncologist- Northern Centre for Cancer Care, Newcastle Upon Tyne, UK
2010-current	Senior Consultant, Radiation Oncology, Tata Medical Center, Kolkata

Other Experience and Professional Memberships

2001	Member, Royal College of Physicians of UK
2006	Fellow, Royal College of Radiologists, London
2009-	Fellow, Royal College of Physicians of Edinburgh
2009-	Fellow, Higher Education Academy of UK
2018	External Examiner in clinical Oncology (University of Malaya)
2019	Examiner of the National Board (DNB in Radiation Oncology)- India
2020	Examiner (invited) Royal College of Radiologists of UK

Honors

2007	Royal College of Radiologists of UK, Short Project Grant Recipent
2008	Council Member, British Association of Head and Neck Oncologists

C. Contribution to Science

1. My contributions in improving outcomes of head and neck cancers include that of using metabolic image guidance to improve target volume definition, investiogate carotid morbidity sparing radiotherapy and formulate dose escalation strategies in head and neck cancers. I have also investigated patient choices in Eastern India on the morbidity versus cure rate benefit in such patients. I highlight the head and neck cancer publications of relevance I have lead:
   a) S Chatterjee et al; Variation in Radiotherapy Target Volume Definition, Dose to Organs at Risk and Clinical Target Volumes Using Anatomic (Computed Tomography) Versus Combined Anatomic and Molecular Imaging (Positron Emission Tomography/Computed Tomography): Intensity-Modulated Radiotherapy Delivered Using a Tomotherapy Hi Art Machine: Final Results of the VortigERN Study Clin Oncol (R Coll Radiol) 2012 Dec;24(10):e173-9
   b) S chatterjee et al; Feasibility of PET-CT Based Hypofractionated Accelerated Dose Escalation in Oropharyngeal Cancers: Final Dosimetric Results of the VORTIGERN Study. (Secondary Endpoint of UK NCRI Portfolio: MREC No: 08/H0907/127, UKCRN ID 7341 J Cancer Res Ther. Apr-Jun 2015;11(2):391-6
   c) S chatterjee et al; Helical Radiotherapy in Early Laryngeal Cancers Could Lead to Excess Local Recurrence: Lessons From a Phase II Prospective Study . Clin Oncol (R Coll Radiol) 2020 Feb;32(2):e67-e75
   d) S Sarkar, S Chatterjee et al; Patient's choice of treatment options with CTRT in head neck cancer: a study of patient preference and decision regret. Radiotherapy and Oncology 115:S145

My other interest is in breast cancer and as the Principal investigatorI am conducting a Phase I/II (CTRI/2015/12/006407) and also a Phase III radiotherapy studies for breast cancer outcome improvement.(NCT03788213). Rellevant publications is as below:

a) S Chatterjee et al; Palliative radiotherapy (RT) to the breast using a novel hypofractionated radiotherapy regime: Results of the HYPORT phase I/II study (CTRI/2015/12/006407). May 2018 Journal of Clinical Oncology 36(15_suppl)

b) S Chatterjee et al; Simultaneous Integrated Boost: Improving the Patient Journey During Breast Cancer Radiotherapy Safely Clin Oncol (R Coll Radiol). 2019 Apr;31(4):266

c) S Chatterjee et al; Outcomes Following a Moderately Hypofractionated Adjuvant Radiation (START B Type) Schedule for Breast Cancer in an Unscreened Non-Caucasian Population. Clin Oncol (R Coll Radiol). 2016 Oct;28(10):e165-72

Support and/or Scholastic Performance

Ongoing Research Support

Nag Foundation 2020 March
One Week Versus Three Week in Adjuvant Radiotherapy in Breast Cancer (HYPORT Adjuvant Role: PI
Ministry of Human Resources and Development (MHRD, India) 2019

Comprehensive Digital Archive of Cancer Imaging-Radiation Oncology (CHAVI-RO)
Role: PI from Tata Medical Centre and Co-I in application to MHRD

Nag Foundation 2017 March
Role: PI INTELHOPE Study (Dose escalation in Head and Neck Cancers)

Intramural Funding (Tata Medical Center) 2015- ongoing
HYPORT B study – Hypofractionated radiation therapy for palliative treatment of locally advanced breast cancer.
Role: PI

Site specific PI on various sponsored research projects funded by Roche, Novartis, Samsung Bioepis

Articles

1. Chakraborty S, Mallick I, Luu HN, Bhattacharyya T, Arunsingh M, Basu Achari R, et al. Geographic disparities in access to cancer clinical trials in India. Ecancermedicalscience [Internet]. 2021 Jan 5 [cited 2021 Jan 25];15. Available from: https://ecancer.org/en/journal/article/1161-geographic-disparities-in-access-to-cancer-clinical-trials-in-india
2. Jain PV, Das A, Manikantan K, Sharan R, Mallick I, Chatterjee S, et al. Radiation-induced hypothyroidism in patients of oral squamous cell carcinoma: A retrospective analysis of 195 patients. 2021; Available from: http://dx.doi.org/10.4103/ijc.IJC_946_19
3. Chatterjee S, Backianathan S, Lal P, Gupta S, Chakraborty S. Can the FAST-Forward Trial Results be Generalised Across all Breast Cancer Patients? Clin Oncol. 2021 Jan;33(1):e95–6.
4. Mallick I, Chakraborty S, Baral S, Saha S, Lal VH, Sasidharan R, et al. Prioritizing Delivery of Cancer Treatment During a COVID-19 Lockdown: The Experience of a Clinical Oncology Service in India. JCO Glob Oncol. 2021 Jan;7:99–107.
5. Tewary S, Arun I, Ahmed R, Chatterjee S, Mukhopadhyay S. AutoIHC-Analyzer: computer-assisted microscopy for automated membrane extraction/scoring in HER2 molecular markers. J Microsc. 2021 Jan;281(1):87–96.
6. Ghosh S, Maulik S, Chatterjee S, Mallick I, Chakravorty N, Mukherjee J. Prediction of survival outcome based on clinical features and pretreatment 18FDG-PET/CT for HNSCC patients. Comput Methods Programs Biomed. 2020 Oct;195:105669.

7. Chatterjee S, Chakraborty S, HYPORT Adjuvant Author Group. Hypofractionated radiation therapy comparing a standard radiotherapy schedule (over 3 weeks) with a novel 1-week schedule in adjuvant breast cancer: an open-label randomized controlled study (HYPORT-Adjuvant)-study protocol for a multicentre, randomized phase III trial. Trials. 2020 Sep 30;21(1):819.
8. Shrimali RK, Saha A, Arun B, Prasath S, Nallathambi C, Bhoumik S, et al. Setting up a lung stereotactic body radiotherapy service in a tertiary center in Eastern India: The process, quality assurance, and early experience. J Cancer Res Ther. 2020 Jul;16(4):888–99.
9. Gupta P, Saha K, Vinarkar S, Banerjee S, Choudhury SS, Parihar M, et al. Next generation sequencing in lung cancer: An initial experience from India. Curr Probl Cancer. 2020 Jun;44(3):100562.
10. Saha M, Arun I, Ahmed R, Chatterjee S, Chakraborty C. HscoreNet: A Deep network for estrogen and progesterone scoring using breast IHC images. Pattern Recognit. 2020 Jun 1;102:107200.
11. Coles CE, Aristei C, Bliss J, Boersma L, Brunt AM, Chatterjee S, et al. International Guidelines on Radiation Therapy for Breast Cancer During the COVID-19 Pandemic. Clin Oncol. 2020 May;32(5):279–81.
12. Kundu S, Chakraborty S, Chatterjee S, Das S, Achari RB, Mukhopadhyay J, et al. De-Identification of Radiomics Data Retaining Longitudinal Temporal Information. J Med Syst. 2020 Apr 2;44(5):99.
13. Chatterjee S, Mallick I, Chakraborty S, Prasath S, Arunsingh M, Achari RB, et al. Helical Radiotherapy in Early Laryngeal Cancers Could Lead to Excess Local Recurrence: Lessons From a Phase II Prospective Study. Clin Oncol. 2019 Nov 5;32(2):e67–75.
14. Mallick I, Arunsingh M, Chakraborty S, Arun B, Prasath S, Roy P, et al. A Phase I/II Study of Stereotactic Hypofractionated Once-weekly Radiation Therapy (SHORT) for Prostate Cancer. Clin Oncol. 2019 Sep 21;32(2):e39–45.
15. Chakraborty S, Wadasadawala T, Ahmed R, Coles C, Chatterjee S. Breast Cancer Demographics, Types and Management Pathways: Can Western Algorithms be Optimally used in Eastern Countries? Clin Oncol. 2019 Aug 1;31(8):502–9.
16. Mallick I, Das A, Arunsingh M. Moderately Hypofractionated Radiotherapy in Node-positive Prostate Cancer. Clin Oncol. 2019 Apr;31(4):260–4.
17. Datta SS, Ghosal N, Daruvala R, Chakraborty S, Shrimali RK, Van Zanten C, et al. How do clinicians rate patient's performance status using the ECOG performance scale? A mixed-methods exploration of variability in decision-making in oncology. Ecancermedicalscience [Internet]. 2019 Mar 28 [cited 2019 Apr 1];13. Available from: https://ecancer.org/journal/13/full/913-how-do-clinicians-rate-patient-s-performance-status-using-the-ecog-performance-scale-a-mixed-methods-exploration-of-variability-in-decision-making-in-oncology.php
18. Chatterjee S, Mahata A, Mandal S, Chakraborty S. Simultaneous Integrated Boost: Improving the Patient Journey During Breast Cancer Radiotherapy Safely. Clin Oncol. 2018 Dec 29;31(4):266.
19. Arunsingh M, Shrimali RK, Chakraborty S, Arun B, Prasath S, Chatterjee S. Survival Outcomes From Concurrent Chemoradiation for Lung Cancer in Indian Patients are Comparable With Reported UK Outcomes. Clin Oncol [Internet]. 2018 Dec 26; Available from: http://dx.doi.org/10.1016/j.clon.2018.12.002
20. Shrimali RK, Chakraborty S, Prasath S, Arun B, Chatterjee S. Impact of modern radiotherapy techniques on survival outcomes for unselected patients with large volume non-small cell lung cancer. Br J Radiol. 2018 Nov 20;92(1095):20180928.
21. Chatterjee S, Chakraborty S, Moses A, Nallathambi C, Mahata A, Mandal S, et al. Resource requirements and reduction in cardiac mortality from deep inspiration breath hold (DIBH) radiation therapy for left sided breast cancer patients: A prospective service development analysis. Pract Radiat Oncol. 2018 Mar 22;8(6):382–7.
22. Tewary S, Arun I, Ahmed R, Chatterjee S, Chakraborty C. SmartIHC-Analyzer: smartphone assisted microscopic image analytics for automated Ki-67 quantification in breast cancer evaluation. Anal Methods. 2017 Nov 9;9(43):6161–70.
23. Saha M, Arun I, Agarwal S, Ahmed R, Chatterjee S, Chakraborty C. Imprint cytology-based breast malignancy screening: an efficient nuclei segmentation technique: IMPRINT CYTOLOGY-BASED BREAST MALIGNANCY SCREENING. J Microsc. 2017 Nov;268(2):155–71.
24. Tewary S, Arun I, Ahmed R, Chatterjee S, Chakraborty C. AutoIHC-scoring: a machine learning framework for automated Allred scoring of molecular expression in ER- and PR-stained breast cancer tissue: AUTOIHC-SCORING. J Microsc. 2017 Nov;268(2):172–85.

25. Chatterjee S, Agrawal S, Nallathambi C, Ahmed R. Is the Current American Society of Clinical Oncology Guidance on Axillary Management Generalisable for Symptomatic or Unscreened Breast Cancers? Clin Oncol. 2017 Oct;29(10):e172–3.
26. Chatterjee S, Mallick I, Bhaumik S, Silwal SR, Roy S, Das J, et al. Intensifying radiation treatment in advanced/poor prognosis laryngeal, hypopharyngeal (LH), and oropharyngeal cancers (OPC) using PET–CT based dose escalation strategies—INTELHOPE (clin trial.Gov NCT02757222). Int J Radiat Oncol Biol Phys. 2017 Oct;99(2):E327–8.
27. Datta SS, Tripathi L, Varghese R, Logan J, Gessler S, Chatterjee S, et al. Pivotal role of families in doctor-patient communication in oncology: a qualitative study of patients, their relatives and cancer clinicians. Eur J Cancer Care [Internet]. 2017 Sep;26(5). Available from: http://doi.wiley.com/10.1111/ecc.12543
28. Banerjee S, Saha M, Arun I, Basak B, Agarwal S, Ahmed R, et al. Near-set Based Mucin Segmentation in Histopathology Images for Detecting Mucinous Carcinoma. J Med Syst. 2017 Aug 10;41(9):144.
29. Mungle T, Tewary S, Das DK, Arun I, Basak B, Agarwal S, et al. MRF-ANN: a machine learning approach for automated ER scoring of breast cancer immunohistochemical images: MRF-ANN. J Microsc. 2017 Aug;267(2):117–29.
30. Murthy V, Calcuttawala A, Chadha K, d'Cruz A, Krishnamurthy A, Mallick I, et al. Human papillomavirus in head and neck cancer in India: Current status and consensus recommendations. South Asian J Cancer. 2017 Jul;6(3):93–8.
31. Das DK, Mitra P, Chakraborty C, Chatterjee S, Maiti AK, Bose S. Computational approach for mitotic cell detection and its application in oral squamous cell carcinoma. Multidimens Syst Signal Process. 2017 Jul 1;28(3):1031–50.
32. Saha M, Chakraborty C, Arun I, Ahmed R, Chatterjee S. An Advanced Deep Learning Approach for Ki-67 Stained Hotspot Detection and Proliferation Rate Scoring for Prognostic Evaluation of Breast Cancer. Sci Rep. 2017 Jun 12;7(1):3213.
33. Agrawal SK, Chatterjee S, Arun I, Ahmed R. Discordance in Immunohistochemical Status of Breast Cancer Post Neoadjuvant Chemotherapy. Indian J Surg Oncol. 2017 Jun;8(2):245–6.
34. Achari R, Arunsingh M, Badgami RK, Saha A, Chatterjee S, Shrimali RK, et al. High-dose Neural Stem Cell Radiation May Not Improve Survival in Glioblastoma. Clin Oncol. 2017 Jun;29(6):335–43.
35. Chatterjee S, Arun I, Agrawal S, Arunsingh M, Mallick I, Ahmed R. Immunohistochemistry Heterogeneity in Reported Breast Cancer Demographics From India: Triple-Negative Breast Cancer Rates Could Be Lower Than Suggested in Pooled Meta-Analysis. J Glob Oncol. 2017 Apr;3(2):180–1.
36. Tripathi L, Datta SS, Agrawal SK, Chatterjee S, Ahmed R. Stigma Perceived by Women Following Surgery for Breast Cancer. Indian J Med Paediatr Oncol. 2017 Apr;38(2):146–52.
37. Mungle T, Tewary S, Arun I, Basak B, Agarwal S, Ahmed R, et al. Automated characterization and counting of Ki-67 protein for breast cancer prognosis: A quantitative immunohistochemistry approach. Comput Methods Programs Biomed. 2017 Feb;139:149–61.
38. Arunsingh M, Mallick I, Prasath S, Arun B, Sarkar S, Shrimali RK, et al. Acute toxicity and its dosimetric correlates for high-risk prostate cancer treated with moderately hypofractionated radiotherapy. Med Dosim. 2017 Jan 24;42(1):18–23.
39. Shrimali RK, Arunsingh M, Das A, Mallick I, Mahata A, Prasath S, et al. Continuous hyperfractionated accelerated radiotherapy using modern radiotherapy techniques for nonsmall cell lung cancer patients unsuitable for chemoradiation. Indian J Cancer. 2017 Jan;54(1):120–6.
40. Pivot X, Bondarenko IM, Nowecki Z. One-year safety, immunogenicity, and survival results from a phase III study comparing SB3 (a proposed trastuzumab biosimilar) and originator trastuzumab in HER2 …. Annals of [Internet]. 2017; Available from: https://www.annalsofoncology.org/article/S0923-7534(20)37516-5/abstract
41. Shrimali RK, Arunsingh M, Reddy GD, Mandal S, Arun B, Prasath S, et al. Actual gains in dosimetry and treatment delivery efficiency from volumetric modulated arc radiotherapy for inoperable, locally advanced lung cancer over five-field forward-planned intensity-modulated radiotherapy. Indian J Cancer. 2017 Jan;54(1):155–60.
42. Shrimali R, Bhargav J, Arora N, Midha D, Parihar M. 1: Tumours' Achilles' heel, that never was–Experience of re-biopsy on disease progression on EGFR-TKIs in lung cancer (NSCLC) patients from a Cancer Centre in …. Lung [Internet]. 2017; Available from: https://www.researchgate.net/profile/Raj_Shrimali/publication/313541006_1_Tumours'_Achilles'_heel_that_never_was_-_Experience_of_re-biopsy_on_disease_progression_on_EGFR-

TKIs in lung cancer NSCLC patients from a Cancer Centre in Eastern India/links/59c33c82a6fdcc69b9301c15/1-Tumours-Achilles-heel-that-never-was-Experience-of-re-biopsy-on-disease-progression-on-EGFR-TKIs-in-lung-cancer-NSCLC-patients-from-a-Cancer-Centre-in-Eastern-India.pdf
43. Shrimali RK, Mahata A, Reddy GD, Franks KN, Chatterjee S. Pitfalls and Challenges to Consider before Setting up a Lung Cancer Intensity-modulated Radiotherapy Service: A Review of the Reported Clinical Experience. Clin Oncol. 2016 Mar;28(3):185–97.
44. Agrawal S, Banswal L, Saha A, Arun I, Datta SS, Chatterjee S, et al. Progesterone receptors, Pathological Complete Response and early outcome for locally advanced breast cancer - a single centre study. (PPLB - 01). Indian J Surg Oncol. 2016 Dec;7(4):397–406.
45. Chatterjee S, Agrawal S, Nallathambi C, Ahmed R. Is the Current American Society of Clinical Oncology Guidance on Axillary Management Generalisable for Symptomatic or Unscreened Breast Cancers? Clin Oncol. 2017 Oct;29(10):e172–3.
46. Chatterjee S, Arunsingh M, Agrawal S, Dabkara D, Mahata A, Arun I, et al. Outcomes Following a Moderately Hypofractionated Adjuvant Radiation (START B Type) Schedule for Breast Cancer in an Unscreened Non-Caucasian Population. Clin Oncol. 2016 Oct;28(10):e165–72.
47. Manikantan K, Bang B, Sharan R, Mallick I, Chatterjee S, Arun P. Therapeutic Neck Dissection in Oral Squamous Cell Carcinoma: Is Selective Neck Dissection the Way Ahead? Kathmandu Univ Med J. 2016 Jul;14(55):221–5.
48. Leung SCY, Nielsen TO, Zabaglo L, Arun I, Badve SS, Bane AL, et al. Analytical validation of a standardized scoring protocol for Ki67: phase 3 of an international multicenter collaboration. NPJ Breast Cancer. 2016 May 18;2:16014.
49. Mehanna H, Evans M, Beasley M, Chatterjee S, Dilkes M, Homer J, et al. Oropharyngeal cancer: United Kingdom National Multidisciplinary Guidelines. J Laryngol Otol. 2016 May;130(S2):S90–6.
50. Shrimali RK, Mahata A, Reddy GD, Franks KN, Chatterjee S. Pitfalls and Challenges to Consider before Setting up a Lung Cancer Intensity-modulated Radiotherapy Service: A Review of the Reported Clinical Experience. Clin Oncol. 2016 Mar;28(3):185–97.
51. Chatterjee S, Arora N, Parihar M, Midha D. 9 EGFR and EML4-Alk testing for non-small cell lung cancer patients–a single centre experience. Cancer [Internet]. 2016; Available from: https://www.researchgate.net/profile/Raj_Shrimali/publication/295938739_EGFR_and_EMIA-Alk_testing_for_non-small_cell_lung_cancer_patients_a_single_centre_experience/links/5757010a08aef6cbe35f4f6a/EGFR-and-EMIA-Alk-testing-for-non-small-cell-lung-cancer-patients-a-single-centre-experience.pdf
52. Shrimali R, Sen P, Arunsingh M, Mahata A, Mallick I. 121 continuous hyperfractionated accelerated radiotherapy (CHART) using volumetric modulated arc therapy (VMAT) for locally advanced non-small cell lung …. Lung [Internet]. 2016; Available from: https://www.researchgate.net/profile/Raj_Shrimali/publication/292210798_121_Continuous_hyperfractionated_accelerated_radiotherapy_CHART_using_volumetric_modulated_arc_therapy_VMAT_for_locally_advanced_non-small_cell_lung_cancer_NSCLC_-_the_clinical_experience/links/5a3a4232a6fdcc34776b47a8/121-Continuous-hyperfractionated-accelerated-radiotherapy-CHART-using-volumetric-modulated-arc-therapy-VMAT-for-locally-advanced-non-small-cell-lung-cancer-NSCLC-the-clinical-experience.pdf
53. Chatterjee S, Saha A, Arun I, Nayak SS, Sinha S, Agrawal S, et al. Correlation of clinicopathological outcomes with changes in IHC4 status after NACT in locally advanced breast cancers: do pre-NACT ER/PR status act as better prognosticators? Breast Cancer. 2015 Dec 10;7:381–8.
54. Chatterjee S, Pilaka VKR, Mukhopadhyay S, Shrimali RK, Ahmed R. Docetaxel-induced Haemorrhagic Interstitial Pneumonitis - An Acute Life-threatening Adverse Effect. Clin Oncol. 2015 Aug;27(8):483–4.
55. Saha A, Mahata A, Shrimali R, Achari R, Mallick I, Chatterjee S. Helical tomotherapy based intensity modulated radiotherapy for the management of difficult clinical situations in breast cancer. Clin Cancer Investig J. 2015;4(4):543.
56. Prasad D, Das P, Saha NS, Chatterjee S, Achari R, Mallick I. Image guidance in prostate cancer - can offline corrections be an effective substitute for daily online imaging? J Cancer Res Ther. 2014 Jan;10(1):21–5.
57. Nandi M, Mahata A, Mallick I, Achari R, Chatterjee S. Hypofractionated radiotherapy for breast cancers--preliminary results from a tertiary care center in eastern India. Asian Pac J Cancer Prev. 2014;15(6):2505–10.

58. Basu Achari R, Gowardhanan D, Arun B, Dharmendran P, Prasath S, Chatterjee S, et al. Three-dimensional conformal radiation therapy, volumetric intensity modulated arc therapy, and helical tomotherapy for pediatric craniospinal irradiation: Dosimetric analysis of integral dose. Int J Radiat Oncol Biol Phys. 2013 Oct;87(2):S591–2.
59. Chatterjee S, Guha S, Prasath S, Mallick I, Achari R. Carotid sparing hypofractionated tomotherapy in early glottic cancers: Refining image guided IMRT to improve morbidity. J Cancer Res Ther. 2013 Jul;9(3):452–5.

Conference Abstracts

1. De Laurentiis M, Borstnar S, Campone M, Warner E, Salvador Bofill J, Jacot W, et al. Updated results from the phase IIIb complement-1 study of ribociclib (RIB) plus letrozole (LET) in the treatment of HR+, HER2-advanced breast cancer (ABC). In Wolters Kluwer; 2020. p. 1055–1055.
2. Arunsingh M, Nallathambi C, Prasath S, Balakrishnan A, Shrimali RK, Achari R, et al. EP-1064: Does parotid sparing adaptive radiotherapy (PSART) benefit patients? Interim results of PARITY study. In Elsevier BV; 2017. p. S585.
3. Saha A, Goswami G, Mandal S, Mahata A, Midha D, Ahmed R, et al. EP-1763: Acute toxicity and in-vivo dosimetry of a two week hypofractionated schedule within the HYPORT study. In Elsevier BV; 2017. p. S970.
4. Tewary S, Chakraborty C, Mahanta LB, Arun I, Ahmed R, Chatterjee S. AutoIHC-analyzer: Computer assisted microscopy for automated evaluation of ER, PR and Ki-67 molecular markers. In: 2017 2nd International Conference for Convergence in Technology (I2CT). ieeexplore.ieee.org; 2017. p. 1049–53.
5. Roy P, Arun I, Mallick I, Banerjee S, Roy M. The importance of lymph node yield and the lymph node ratio after neoadjuvant chemoradiation in rectal cancer. In Elsevier BV; 2017. p. e79.
6. Chatterjee S, Arunsingh M, Agrawal S, Dabkara D, Mahata A, Arun I, et al. Demographics and outcomes of breast cancer patients treated at Tata medical center, Kolkata. In Elsevier BV; 2017. p. e76.
7. Arunsingh M, Mahata A, Mandal S, Sadhukan A, Shrimali RK, Achari R, et al. How Much Extra Resource do we Spend to Protect the Heart from Radiation Damage and for What Gain? In Elsevier; 2017. p. e76.
8. Roy M, Bhutia T, Banerjee S, Thambudorai R, Roy P, Dabkara D, et al. Feasibility of D2 Gastrectomy in Eastern India: Early Results. In Elsevier; 2017. p. e82.
9. Thangjam D, Agrawal SK, Chatterjee S, Ahmed R. Nottingham Prognostic index (NPI) – a Simple Predictive Tool for Operable Breast Cancer. In Elsevier; 2017. p. e75.
10. Chatterjee S, Saha A, Badgami RK, Sen P, Midha D, Sinha S, et al. Quality assurance and acute toxicities of a 2 week hypofractionated palliative radiotherapy schedule used in a prospective phase I/II study (HYPORT study). In Elsevier BV; 2017. p. e74.
11. Arunsingh M, Sriram Prasath S, Arun B, Shrimali RK, Chatterjee S, Achari R, et al. Intensity-modulated Radiotherapy (IMRT) in Anal Squamous Cell Carcinoma (SCC) - Acute Toxicity Profile and Preliminary Clinical Outcomes. In Elsevier; 2017. p. e78–9.
12. Mallick I, Arunsingh M, Gupta S, Mukherjee S, Chatterjee S, Shrimali RK, et al. Health-related quality of life outcomes in a phase I/II study of stereotactic hypofractionated once-weekly radiation therapy (SHORT) for nonmetastatic prostate cancer. In Wolters Kluwer; 2017. p. 126–126.
13. Chatterjee S, Arun P, Manikantan K. Risk Stratification In Early Stage Node Negative Oral Cancer-The Impact Of Prognostic Factors And The Proposed 8Th Edition Staging System. In 2017.
14. Roy P, Honap SN, Arun I, Thambudorai R, Mallick I. Interobserver Variability of Histopathological Regression Scoring Systems Following Neoadjuvant Chemo-Radiotherapy in Esophageal Cancer. In: LABORATORY INVESTIGATION. NATURE PUBLISHING GROUP 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA; 2017. p. 198A – 198A.
15. Choraria A, Agrawal S, Arun I. Predicting sentinel and non-sentinel lymph node metastasis–are MSKCC nomograms valid for non-screened breast cancer patients? In clinicaloncologyonline.net; 2017. Available from: https://www.clinicaloncologyonline.net/article/S0936-6555(16)30368-5/fulltext
16. Agrawal S, Chatterjee S, Bansawal L, Arun I, Datta S, Ahmed R. Sentinel lymph node biopsy after initial lumpectomy (SNAIL study). In: ANNALS OF SURGICAL ONCOLOGY. SPRINGER 233 SPRING ST, NEW YORK, NY 10013 USA; 2017. p. 151–2.

17. Shrimali R, Bhargav J, Arora N, Midha D, Mishra D, Parihar M, et al. 76: Double whammy or double bonanza? Report of compound/double EGFR mutation in NSCLC patients from a cancer centre in Eastern India. In Elsevier BV; 2017. p. S36.
18. Choraria A, Agrawal S, Chandra A, Sen S, Chatterjee S, Ahmed R. Accuracy of clinico-radiological methods in diagnosing axillary lymph node metastasis in carcinoma breast. In Wolters Kluwer; 2016. p. e18147–e18147.
19. Mallick I, Achari R, Chatterjee S, Shrimali R, Prasath S, Arun B, et al. OC-0373: IGRTonline: development and evaluation of a free online course on Image Guided Radiation Therapy. In Elsevier BV; 2016. p. S174.
20. Arunsingh M, Mahato A, Sadhukan A, Achari R, Mallick I, Shrimali RK, et al. EP-1456: What is the cost of reducing cardiac morbidities when treating breast cancers with radiotherapy? In Elsevier BV; 2016. p. S675.
21. Mallick I, Bhaumik S, Sarkar K, Arun P, Manikantan K, Roy P, et al. EP-1042: Risk-factors in pT1-2N0M0 squamous cancers of the oral cavity and the role of adjuvant radiotherapy. In Elsevier BV; 2016. p. S503–4.
22. Dowsett M, Leung SCY, Zabaglo L, Arun I, Badve SS, Bane AL, et al. Abstract P1-01-01: Analytical validation of a standardized scoring protocol for Ki67: Phase-3 of an international multicenter collaboration. In American Association for Cancer Research; 2016. p. P1–01 – 01–P1 – 01–01.
23. Arunsingh M, Shrimali R, Dabkara D, Biswas B, Midha D, Parihar M, et al. 58 Crizotinib toxicity, dose adjustments and initial response: a single centre experience. In Elsevier BV; 2016. p. S21–2.
24. Achari RB, Saha A, Badgami RK, Chatterjee S, Shrimali RK, Mallick I, et al. NEURAL STEM CELL NICHE INVOLVEMENT AND PATTERNS OF FAILURE IN GLIOBLASTOMA MULTIFORME. In: NEURO-ONCOLOGY. OXFORD UNIV PRESS INC JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA; 2016. p. 177–177.
25. Veduruparthi BK, Mukherjee J, Das PP, Chatterjee S, Ray S, Sen P. Multimodal image registration of lung images. In: 2015 Fifth National Conference on Computer Vision, Pattern Recognition, Image Processing and Graphics (NCVPRIPG). ieeexplore.ieee.org; 2015. p. 1–4.
26. Pilaka V, Sarkar K, Ahmed R, Mahata A, Mallick I, Shrimali RK, et al. PO-0788: Do heart and lung distances correlate to DVH when irradiating with forward planned IMRT techniques in breast cancer? In Elsevier BV; 2015. p. S394.
27. Chatterjee S, Reddy VK, Sarkar K, Ahmed R, Mahata A, Mallick I, et al. PO-0690: Answering questions for hypofractionated RT in Indian breast cancers: analysis of toxicities and outcomes. In Elsevier BV; 2015. p. S337–8.
28. Saha A, Mallick I, Das P, Majumdar A, Mahata A, Chatterjee S, et al. PO-0775: Can daily image guidance be avoided for Helical Tomotherapy in head and neck cancers? A prospective validation study. In Elsevier BV; 2015. p. S386.
29. Arunsingh M, Roy B, Achari R, Tamilselvan S, Shrimali R, Mallick I, et al. PO-1115 Hypofractionated radiotherapy in early glottic cancers ñ analysis of image guidance and clinical factors on outcome. In Elsevier BV; 2015. p. S604.
30. Ahmed R, Agrawal S, Arun I, Datta SS. P083. Breast oncological surgery in a resource poor country–Patient presentation and early outcome. In ejso.com; 2015. Available from: https://www.ejso.com/article/S0748-7983(15)00226-7/abstract
31. Roy P, Nayak S, Arun I, Midha D, Pattatheyil A, Manikantan K, et al. Predictive Factors and Topography of Nodal Metastases From Oral Cavity Squamous Cell Carcinoma-an Audit of 304 Cases Undergoing Primary Surgical Resection. In: LABORATORY INVESTIGATION. NATURE PUBLISHING GROUP 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA; 2015. p. 329A – 329A.
32. Saha M, Agarwal S, Arun I, Ahmed R, Chatterjee S, Mitra P, et al. Histogram Based Thresholding for Automated Nucleus Segmentation Using Breast Imprint Cytology. In: Advancements of Medical Electronics. Springer India; 2015. p. 49–57.
33. Bang BA, Arun P, Sharan R, Chatterjee S. Infratemporal fossa clearance for oral squamous cancer: Is it time to shift the paradigm. In Wolters Kluwer; 2014. p. e17047–e17047.
34. Agrawal S, Chattorjee S, Ghosh I, Ahmed R. P0103 Results of breast conserving surgery in locally advanced breast cancer following neoadjuvant chemotherapy. In Elsevier; 2014. p. e37–8.
35. Arunsingh SM, Dharmendran P, Mahata A, Chatterjee S, Mallick I, Achari R. PO-1008: Adaptive brachytherapy for carcinoma cervix ñ analyzing CT versus MRI for volume delineation. In Elsevier BV; 2014. p. S148.

36. Reddy G, Shrimali RK, Dharmendran P, Achari R, Mallick I, Chatterjee S. EP-1163: Volumetric modulated arc therapy (VMAT)in locally advanced lung cancer ñ dosimetric comparison with 3DCRT. In Elsevier BV; 2014. p. S42.
37. Chatterjee S, Chakraborty S, Das S, Tamil Selvan S, Shrimali RK, Achari R, et al. EP-1198: Cavity Boost (CB) following Fractionated External Beam Radiotherapy (EBRT): Time to move on from clinical mark-ups? In Elsevier BV; 2014. p. S54–5.
38. Chakraborty S, Sarkar S, Agarwal N, Ahmed R, Chatterjee S, Ghosh I. Are breast cancers in India different from Western populations? Results of a tertiary center retrospective analysis. In Wolters Kluwer; 2013. p. e12039–e12039.
39. Mallick I, Das S, Sriram Prasath S, Dharmendran P, Achari R, Chatterjee S. EP-1085: Hypofractionated radiotherapy for localized prostate cancer ñ acute toxicity and dosimetric correlates. In Elsevier BV; 2013. p. S411–2.
40. Chatterjee S, Sarkar S, Bang B, Sharan R, Pattatheyil A, Prasath S, et al. EP-1023: Challenges in treatment of oral cavity squamous cell carcinoma in a tertiary care centre in India. In Elsevier BV; 2013. p. S392.
41. Nandi M, Mahata A, Selvan T, Mallick I, Achari R, Chatterjee S. EP-1063: Helical Tomotherapy vs. 3dCRT in adjuvant radiotherapy of breast cancer: comparative dosimetry. In Elsevier BV; 2013. p. S405.
42. Achari R, Guha S, Chandra A, Sen S, Mahata A, Chatterjee S, et al. PD-0466: Apparent diffusion coefficient in carcinoma cervix: an imaging biomarker for radiation response. In Elsevier BV; 2013. p. S181.
43. Sarkar S, Mahata A, Ray R, Guha S, Mallick I, Achair R, et al. EP-1016: Can Weight loss alert adaptive planning to reduce parotid gland dose? A correlative study to guide adaptive radiation. In Elsevier BV; 2013. p. S389–90.
44. Saha A, Goswami G, Saha M, Mahata A, Mandal S, Midha D, et al. EP-1763 Acute toxicity and in-vivo dosimetry of a two week hypofractionated schedule within the HYPORT study. In. Available from: http://dx.doi.org/10.1016/S0167-8140(17)32126-6